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ABSTRACT
Preeclampsia has major symptoms of hypertension and proteinuria and is a cause of significant maternal
and infant mortality in the world. The slow development of preeclampsia research possibility created by the diffi -
culty in acquiring animal preeclampsia. Many existing animal model have been developed, but most of them are
expensive to do. The purpose of this study was to determine the effects of intraperitoneal injection of pregnant pa-
tients serum with high TNF-α levels toward sFlt-1 serum concentration and blood pressure of pregnant mice.
Pregnant patients serum with high TNF-α levels (>20 pg/mL) was injected intraperitoneally to pregnant mice at
gestational age 13 and 14 days. At 18 days of gestation, the blood pressure was measured, then the mice were dis -
sected and the serum was taken to measure serum sFlt-1 concentration using ELISA kit (Bioassay Technology
Laboratory, E0611Mo). The results showed there was a significant increase in blood pressure (p= 0.000) and the
sFlt-1 levels (p= 0.002) of injected pregnant mice group compare to control group. These finding demonstrated
that intraperitoneal injection of pregnant patients serum with high TNF-α levels to pregnant mice can increase
blood pressure and sFlt-1 serum concentration of mice.
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Preeclampsia is a syndrome in pregnancy that oc-
curs in over 20 weeks of gestational age, with hyperten-
sion  and  proteinuria  as  the  main  symptoms  [1].
Preeclampsia is a cause of maternal and infant mortal-
ity in the world and also can lead 12-25% occurrence
of fetal growth restriction. The incidence of preeclamp-
sia ranges from 3% to 10% of pregnancies worldwide,
and the impact of preeclampsia is  more prevalent in
developing countries [2].
Preeclampsia is preceded by the disruption of the
placental invasion of the endometrium [3]. These con-
ditions will cause placental hypoxia that can lead the
placental damage, followed by high inflammatory and
immune responses in the placenta. Activated immune
responses  will  result  in producing the angiotensin II
type 1 receptor autoantibodies (AT1-AA) which then
synthesize TNF-α [4]. Tumor necrosis factor α (TNF-
α) induces the formation of high antiangiogenic factor
levels in serum, one of which is soluble fms-like tyro-
sine kinase-1 (sFlt-1).
The sFlt-1 is a vascular endothelial  growth factor
receptor 1 (VEGFR-1) or Flt-1 that lack of transmem-
brane and a cytoplasmic domain. The sFlt-1 is not bind
on the plasma membrane of the endothelial  cell  but
soluble in the serum. This lack of transmembrane and
cytoplasmic domain make the sFlt-1 can not continue
the second messenger of this receptor. [5]. The increas-
ing of sFlt-1 serum levels resulting in decreasing serum
levels of it is a ligand, the vascular endothelial growth
factor  (VEGF),  and  placental  growth  factor  (PlGF).
The decreasing of VEGF and PlGF will cause clinical
symptoms of preeclampsia like hypertension and pro-
teinuria [6].
One  of  the  preeclampsia  treatments  is  by  giving
magnesium sulfate to prevent seizures. However, this
treatment does not treat or decrease the progression of
preeclampsia [1, 7]. The slow progress of research in
finding therapies preeclampsia likely influenced by the
difficulty of obtaining experimental preeclampsia ani-
mal  models.  A previous study revealed that injecting
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TNF-α in pregnant mice will lead to hypertension and
proteinuria [8].
Hence in this study we want to know the effects of
intraperitoneal  injection  of  pregnant  patients  serum
with high TNF-α levels toward sFlt-1 serum levels and
blood  pressure  of  pregnant  mice.  We  also  want  to
know  whether  this  study  method  possibility  can  be
used as preeclampsia mice model. 
Experimental Design
This research is a purely experimental (true experi-
mental)  laboratory  study  using  a  posttest  only  con-
trolled group design. This study was performed in vivo
to determine the effects of intraperitoneal injection of
pregnant  patients  serum with  high  levels  of  TNF-α
(>20  pg/mL)  toward sFlt-1  serum concentration and
blood pressure in pregnant mice.
Experimental Subjects
This study used pregnant patients as serum sources
and pregnant mice as an experimental  subject.  Preg-
nant patients were patients who control to Obstetrics
Department of dr. Saiful Anwar Hospital at age 28-35
years and 30-40 weeks gestation with an agreement to
participate  in  this  study.  Serum was  collected  from
pregnant patients serum with TNF-α levels more than
20 pg/mL. Patients with infectious diseases and other
chronic diseases are excluded from this study. Pregnant
mice were used as many as 18 mice and were divided
into two groups (each group consists  of  nine mice).
One group was not injected and included as a control
group,  and  the  other  group  was  injected  with  the
serum of  pregnant  patients  with  high  TNF-α levels
(TNF-α group). This study was approved by the Ethics
Committee of the Faculty of Medicine, University of
Brawijaya.
Pregnant Patients TNF-α Serum Levels Measurement
Blood was drawn from a pregnant patients vein us-
ing five cc syringe and put in plain vacutainer. Blood
stored in a refrigerator at 4°C for 12 hours and then
centrifuged at  6000 rpm for 10 minutes.  Serum was
taken and measured for the TNF-α levels using ELISA
kit (BioLegend, USA, catalog number 430207). Serum
with high levels of TNF-α then grouped and homoge-
nized by the strong mixture. After measuring TNF-α
levels  in  the  serum with  ELISA,  we  found that  the
mean of  TNF-α serum levels  from six  pregnant  pa-
tients were 27.59 ± 5.39 pg/mL.
Serum Intraperitoneal Injection
Pregnant  patients  serum with  high  TNF-α levels
(0.1 cc) was injected to pregnant mice at the age of 13
and 14 days of pregnancy [4, 9]. The Serum was in-
jected on intraperitoneal of the upper right abdomen
with a slope of 45° and 0.5 cm deep with one cc sy-
ringe and 27G needle.
Blood Pressure Measurement
Mice blood pressure was measured at the age of 18
days of pregnancy before dissected. Mice were placed
on mice stabilizer then mounted by the cuff and pulse
recorded on the tail. Mice non-invasive blood pressure
measuring machine (UgoBasile, Italy, product number
58500) was stand run to measure systolic and diastolic
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Figure  1.  Pregnant  Mice  Blood  Pressure.  Serum with  high  TNF-α levels  was  injected  intraperitoneally  to  pregnant  mice  at
gestational age 13 and 14 days. Mice blood pressure was measured at gestational age 18 days. Injection of serum with
high TNF-α levels to injected mice group resulted in increased of systolic and diastolic blood pressure compare to control
group (*showed significantly different, p<0.05)
 Bramantyo Aji Wicaksono et al., 2015
blood pressure of mice. The measurement results were
analyzed using independent t-test analysis.
Mice sFlt-1 Serum Levels Measurement
Mice were dissected at the age of 18 days of preg-
nancy using chloroform. Mice blood was taken directly
from the right heart using one cc syringe and 27G nee-
dle. Blood was stored in a refrigerator at 4°C for 12
hours and then centrifuged at 6000 rpm for 10 min-
utes.  Serum was taken and measured the sFlt-1levels
using  ELISA  kit  (Bioassay  Technology  Laboratory,
China,  catalog number E0611Mo).  The measurement
results were analyzed using independent t-test analysis.
Mice Blood Pressure
We injected serum with high TNF-α levels to the
injected mice group as described above and measured
their systolic and diastolic blood pressure. Systolic and
diastolic blood pressure increase in the group of mice
injected with serum with high TNF-α levels. The re-
sults of measurements of systolic and diastolic blood
pressure can be seen in Figure 1.
This  study  used  independent  t-test  analysis  (p
<0.05) on systolic and diastolic blood pressure. There
was a significant increase in the systolic blood pressure
in mice group injected with serum with high TNF-α
levels  compare  to  control  group (189.56  ±  17.91  vs.
137.89 ± 12.83; p=0.00). The diastolic blood pressure
also significantly increase, and there was a significant
difference  between  mice  group  injected  with  serum
with high TNF-α levels and control group (81.78 ± 3.8
vs. 66.78 ± 10.8; p=0.01).
Mice sFlt-1 Serum Levels
We injected serum with high TNF-α levels to the
injected mice group as described above and measured
their sFlt-1 serum levels using ELISA kit. Mice sFlt-1
serum levels  increase  in  the  group  of  mice  injected
with  serum with  high  TNF-α levels.  The  results  of
measurements  of  serum levels  of  sFlt-1  mice  can be
seen in Figure 2. This study used independent t-test
analysis (p <0.05) on sFlt-1 serum levels. There was a
significant increase of sFlt-1 serum levels in mice group
injected with serum with high TNF-α levels compare
to control group (6.73 ± 2.36 vs. 3.2 ± 1.53; p=0.00). 
This study showed that intraperitoneal injection of
serum  with  high  TNF-α levels  may  increase  sFlt-1
serum  levels  of  pregnant  mice.  The  TNF-α in  the
serum may bind with mice TNF-α receptor. This bind-
ing stimulate the formation of hypoxia-inducible factor
1 (HIF-1) by increase the transcription of HIF-1 sub-
unit, the HIF-1α [10]. The HIF-1 acts as a transcrip-
tion activator protein of sFlt-1 [11]. The HIF-1 is con-
sisted of HIF-1α and HIF-1β subunits. The HIF-1β is
an HIF-1 subunit expressed in constant, whereas HIF-
1α is an HIF-1 subunit that normally expressed stably
in  hypoxic  conditions  by  blocking  its  breakdown
mechanism.  To  perform  its  functions  as  activating
transcription  of  a  gene,  HIF-1α and  HIF-1β should
form dimers into HIF-1 [12]. In a normal oxygen con-
dition (normoxia) HIF-1α is hydroxylated, acetylated,
polyubiquitinated and braked down by the proteasome.
All of that mechanism is oxygen dependent. Therefore,
the amount of HIF-1α is low and can not bound with
HIF-1  β to become HIF-1 dimer [13]. In conditions of
high inflammatory factors, such in high levels of TNF-
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Figure 2. sFlt-1 Serum Levels of Pregnant Mice. Serum with high TNF-α levels was injected intraperitoneally to pregnant mice at
gestational age 13 and 14 days. Mice was dissected at a gestational age of 18 days, and the serum was taken from the heart.
Injection of serum with high TNF-α levels to injected mice group resulted in increased of sFlt-1 serum levels compare to
control group. (*showed significantly different, p<0.05)
Intraperitoneal Injection of High Tumor Necrosis Factor (TNF-α) Serum
α, HIF-1α can be synthesized with higher numbers de-
spite  normoxia.  The  TNF-α will  activate  NFκB,  a
transcription  factor  that  has  a  downstream signal  to
HIF-1α gene transcription so that HIF-1α will be syn-
thesized  more  and  expressed  stably  [14].  The  high
number of HIF-1, sFlt-1synthesis will be increased.
Tumor necrosis factor α (TNF-α) will also increase
IL-6, which is the product of TNF-α downstream sig-
nal. The previous data showed that there is higher lev-
els of TNF-α and IL-6 in patients with preeclampsia
compare  to  normal  pregnant  patients  [15,  16].  The
high levels of IL-6 will induce the differentiation of T
cells into Th17 cells and followed by decreasing in the
regulatory function of Treg cells that would reduce the
ratio of Treg: Th17 [17]. This condition will activate
response  and  differentiation  of  B  cells  into  B  cells
CD19+ CD5+. These type of B cells  are autoreactive
cells that can secrete high angiotensin II type 1 recep-
tor agonistic autoantibodies (AT1-AA) in patients with
preeclampsia  [18].  The  AT1-AA  that  is  formed  will
bind and activate  angiotensin 1 receptor (AT1).  The
activated AT1 receptor will further increase the produc-
tion of TNF-α and forming more sFlt-1 [4].
This study also showed that intraperitoneal injec-
tion  of  serum with  high  TNF-α levels  will  increase
blood pressure  pregnant  mice.  Increased  blood pres-
sure is caused by high levels of sFlt-1 that will decrease
angiogenic factors, such as VEGF and PlGF [6]. De-
creased VEGF and PlGF will reduce the bond between
VEGF to VEGFR-1 and VEGFR-2, and the bond be-
tween PlGF with VEGFR-1. Reduction of VEGFR-2 ac-
tivation will reduce activation of eNOS that have an ef-
fect on the reduction of NO synthesis [19]. Nitric Ox-
ide  (NO)  is  a  natural  vasodilator  blood  vessels  and
serves  to  maintain  the  permeability  of  blood  vessels
[20].  Reduced NO in blood vessels  will  increase en-
dothelin 1 (ET-1) which is a blood vessels vasoconstric-
tor, thus causing hypertension [21, 22].
Vasoconstriction that occurs in blood vessels due to
the presence of ET-1 will cause endothelial dysfunction
or damage to the endothelium [22]. Endothelial  dys-
function that occurs in the kidneys will cause damage
to  the  kidney  glomerulus,  thus  causing  proteinuria
[23].  Endothelial  dysfunction that  occurs  in  the  pla-
centa will cause disruption of placental vascularization
[24]. Disruption of placental vascularization will aggra-
vate the condition of preeclampsia because it will in-
crease the damage to the placenta and increase the pla-
centa inflammatory condition [25].
This research has shown the possibility of pregnant
patients  serum with high TNF-α levels  injected into
pregnant mice can mimic preeclampsia condition such
hypertension and increase sFlt-1 serum concentration.
However, some limitations are also found in this study.
In our present study, we did not evaluate urine protein
levels of mice that indicate proteinuria which also the
main symptom of preeclampsia. Moreover, we did not
evaluate  the  mechanism  of  how  pregnant  patients
serum with high TNF-α levels can cause hypertension
and increase of sFlt-1 serum concentration. Measure-
ment of VEGF and PlGF serum concentration may be
useful to explain that mechanism. Therefore, this does
not rule out the possibility of opening further research
in the future to cover the limitations of this study.
The results of this present study indicate that preg-
nant  patients  serum  with  high  TNF-  α levels  that
injected into pregnant mice can increase blood pressure
and  sFlt-1  serum  concentration  of  mice.  Thus,  our
present  study  may  be  developed  as  an  experimental
mice model for preeclampsia.
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